July 22, 2020 – Pfizer Inc. (New York, NY) and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) to meet the U.S. government’s “Operation Warp Speed” program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.
Under the agreement, the U.S. government will receive 100 million doses of BNT162, the COVID-19 vaccine candidate jointly developed by Pfizer and BioNTech, after Pfizer successfully manufactures and obtains approval or emergency use authorization from U.S. Food and Drug Administration (FDA).
The U.S. government will pay the companies $1.95 billion upon the receipt of the first 100 million doses, following FDA authorization or approval. The U.S. government also can acquire up to an additional 500 million doses. Americans will receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines.
The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies and are not currently approved for distribution anywhere in the world…